Arthralgia intravenous

Indications for use of parenteral iron, e.g. as fer-rioxidesaccharate or iron dextran, are in patients on hemodialysis and patients with a disease which prevents absorption from the gastrointestinal tract, in patients who are on long term parenteral nutrition and sometimes in patients with inflammatory bowel disease. Parenteral iron does not raise the hemoglobin level significantly faster than oral therapy and carries a risk of severe adverse reactions. Reactions to intravenous iron include headache, malaise, fever, arthralgias, urticaria and in rare cases anaphylactic reactions, which may be fatal. 

Idursulfase (Elaprase) is a drug used to treat mucopolysaccharidosis II or Hunter syndrome. It is a lysosomal storage disease caused by iduronate-2-sulfatase deficiency. Idursulfase is a purified form of iduronate-2-sulfatase produced by recombinant DNA technology in a human cell line. The drug provides clinically important benefits to Hunter syndrome patients. After intravenous infusion Idursulfase is eliminated by peptide hydrolysis with an elimination half-life of 45 minutes. The most common adverse events are hypersensitivity reactions, pyrexia, headache and arthralgia. 

Flulike symptoms, including fever, chills, weakness, fatigue, myalgia, and arthralgia, are the most common side effects of interferon therapy. These symptoms occur in more than 50% of patients given injections of interferons either intravenously, intramuscularly, or subcutaneously. Intralesional injection may produce milder flulike symptoms with somewhat less frequency. Tolerance to these symptoms generally develops with repeated dosing. 

In a comparison of intravenous and oral ciprofloxacin in children, treatment associated adverse events were reported in 11% of children taking oral ciprofloxacin, compared with 19% of the children who were treated intravenously (68). In 31 children (1.5%) arthralgia occurred, but it was generally mild to moderate and resolved spontaneously. 

Infusion of intravenous immunoglobulin 0.14 g/kg in 17 patients with autoimmune diseases, in whom circulating immunoglobulins had been depleted, was associated with a high incidence of serious adverse effects (94). Treatment was terminated in four patients because of adverse effects, including urticaria, severe hypotension, arthralgia, and chest discomfort. 

Reactions to intravenous iron include headache, malaise, fever, generalized lymphadenopathy arthralgias, urticaria, and in some patients with rheumatoid arthritis, exacerbation of the disease. Phlebitis may occur with prolonged infusions of a concentrated solution or when an intramuscular preparation containing 0.5% phenol is used in error. Of greatest concern is the rare anaphylactic reaction, which may be fatal despite treatment. 

Antibiotics Synercid is the combination of quinupristin and dalfopristin bactericidal inhibitors of protein synthesis. Intravenous use for drug-resistant gram-positive cocci including MRSA, VRE, and pneumococci. Tox infusion-related pain, arthralgia, myalgia. 

In a study in which 65 patients switched from intravenous immunoglobulin to subcutaneous immunoglobulins, three patients discontinued subcutaneous administration because of fever, myalgia, and arthralgia in the days after the infusion and switched back to intravenous immunoglobulin [64 ]. 

Observational studies The efficacy of pulse pamidronate therapy in NSAID-refractory active ankylosing spondylitis has been assessed in 52 patients using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 47 completed the study [9 ]. They were given an NSAID and monthly intravenous infusions of pamidronate 60 mg for 6 months. The most common adverse reactions were arthralgia and myalgia, in 11 cases each, after the initial infusions. There were five withdrawals two defaults, one for a hip joint replacement, and two because of asymptomatic rises in serum creatinine. 

---